Aptamers: a new class of oligonucleotides in the drug discovery pipeline?

被引：59

作者：

Dausse, Eric ^{[1
,2
]}

Gomes, Sonia Da Rocha ^{[3
]}

Toulme, Jean-Jacques ^{[1
,2
]}

机构：

[1] INSERM, U869, F-33076 Bordeaux, France

[2] Univ Bordeaux, IECB, Bordeaux, France

[3] Novaptech, European Inst Chem & Biol, F-33607 Pessac, France

来源：

CURRENT OPINION IN PHARMACOLOGY | 2009年 / 9卷 / 05期

关键词：

IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VIVO; DNA-POLYMERASE; RNA MOLECULES; TUMOR-CELLS; SELECTION; DELIVERY; THERAPEUTICS; ANTISENSE; INHIBIT;

D O I：

10.1016/j.coph.2009.07.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aptamers are oligonucleotides identified in a randomly synthesized library containing up to 1015 different molecules that fold into defined three-dimensional structures. Following their selection for predetermined properties at the end of an iterative process known as SELEX (Systematic Evolution of Ligands by Exponential enrichment) they can be chemically modified in order to provide them with additional properties. These molecules display both high affinity and specificity for their target. Aptamers constitute promising molecules for therapeutic applications as exemplified by pegaptanib, an aptamer-derived anti-VEGF compound shown to be effective in treating age-related macular degeneration.

引用

页码：602 / 607

页数：6

共 51 条

[1] DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity [J].

Andreola, ML ;

Pileur, F ;

Calmels, C ;

Ventura, M ;

Tarrago-Litvak, L ;

Toulmé, JJ ;

Litvak, S .

BIOCHEMISTRY, 2001, 40 (34) :10087-10094

[2] An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform [J].

Bagalkot, Vaishali ;

Farokhzad, Omid C. ;

Langer, Robert ;

Jon, Sangyong .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2006, 45 (48) :8149-8152

[3] Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer [J].

Bates, Paula J. ;

Laber, Damian A. ;

Miller, Donald M. ;

Thomas, Shelia D. ;

Trent, John O. .

EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2009, 86 (03) :151-164

[4] Non-SELEX selection of aptamers [J].

Berezovski, M ;

Musheev, M ;

Drabovich, A ;

Krylov, SN .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (05) :1410-1411

[5] Aptamers as tools for target validation [J].

Blank, M ;

Blind, M .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (04) :336-342

[6] SELECTION OF SINGLE-STRANDED-DNA MOLECULES THAT BIND AND INHIBIT HUMAN THROMBIN [J].

BOCK, LC ;

GRIFFIN, LC ;

LATHAM, JA ;

VERMAAS, EH ;

TOOLE, JJ .

NATURE, 1992, 355 (6360) :564-566

[7] The promises and pitfalls of RNA-interference-based therapeutics [J].

Castanotto, Daniela ;

Rossi, John J. .

NATURE, 2009, 457 (7228) :426-433

[8] Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library [J].

Charlton, J ;

Kirschenheuter, GP ;

Smith, D .

BIOCHEMISTRY, 1997, 36 (10) :3018-3026

[9] Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells [J].

Chekulaeva, Marina ;

Filipowicz, Witold .

CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (03) :452-460

[10] Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA [J].

Chelliserrykattil, J ;

Ellington, AD .

NATURE BIOTECHNOLOGY, 2004, 22 (09) :1155-1160

← 1 2 3 4 5 6 →